Efficacy and safety of Anti-reflux mucosal ablation for refractory GERD: Multi-center prospective study.

Efficacy and safety of Anti-reflux mucosal ablation for refractory GERD: Multi-center prospective study. - Efficacy and safety of ARMA for GERD: Multi-center prospective study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000045188

Enrollment

100

Registered

2021-08-18

Start date

2021-08-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PPI/PCAB refractory/dependent GERD

Interventions

Place sub-circumferential endoscopic ablation at the gastric cardia utilizing Argon plasma coagulation(APC).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient with PPI/PCAB refractory/dependent GERD.

Exclusion criteria

Exclusion criteria: Inability or unwillingness of patients to give written informed consent. Patient with prominent sliding hernia. Patient with impaired esophageal motility. Pregnancy. Patient with psychiatric/Neurological disorders. Patient with severe comorbidities. Judged unsuitable for this study by the physicians

Design outcomes

Primary

Measure	Time frame
Symptom scores(F scale,GERD-Q,GERD-HRQL,SF-36, Pittsburgh sleep quality index)	—

Secondary

Measure	Time frame
24h pH monitoring(Acid Exposure Time, DeMeester Composite Score, Number of acid exposure, All reflux episode, Symptom Index, Symptom Associated Possibility) Endoscopic image (after 1-3 years) 24h pH monitoring (after 1-3 years) Necessity of PPI/PCAB EPSIS before and after ARMA Adverse event: incidence of bleeding, perforation, stenosis	—

Countries

Japan

Contacts

Public ContactMayo Tanabe

Showa University Koto Toyosu Hospital Digestive Diseases Center

mayo.tanabe@gmail.com+81362046000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026